作为非小细胞肺癌治疗的潜在负面预后/预测生物标志物的RBM10突变

Amanda Reyes1, Michelle Afkhami2, Erminia Massarelli1

  • 1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.

Clinical lung cancer
|August 13, 2024
PubMed
概括

非小细胞肺癌 (NSCLC) 的RNA结合动机10 (RBM10) 突变与更快的疾病进展相关. 然而,像ZFHX3和EGFR这样的并发突变可能表明更稳定的疾病.